Griseofulvin 4-etherified derivatives and their applications
By developing 4-position etherified derivatives of greyfoxomycin, the problem of insufficient inhibition of existing anti-plant pathogenic fungal drugs on various pathogens is solved, and effective inhibition of serious pathogens such as apple anthrax is achieved, with high activity and low Advantages of toxic side effects.
Patent Information
- Application Number
- CN202310137378.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-02-20
AI Technical Summary
The existing anti-phytopathogenic fungal drugs have insufficient inhibitory effect on a variety of plant pathogens, especially in the control of severe pathogens such as apple anthrax.
A series of 4-position etherified derivatives of greyfolicin were developed, and the products were recovered by reaction with bromoalkane in the presence of organic solvents and alkalis, combined with column chromatography separation and other methods, and used to prepare anti-phytopathogenic drugs.
These derivatives have shown significant inhibitory activity on a variety of plant pathogens, including apple anthrax, tomato premature blight, tobacco red star disease, etc., with low IC50 value, especially the inhibitory effect on apple anthrax, and are highly active and toxic. Advantages of small side effects.
Smart Images

Figure CN116199657B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to griseofulvin derivatives and applications thereof, in particular to griseofulvin 4-etherified derivatives, synthesis methods thereof and applications thereof in resisting plant pathogenic fungi. Background Art
[0002] Griseofulvin, also known as griseofulvin, is a natural product isolated from the hyphae of fungi. Since it was isolated, hundreds of derivatives have been synthesized and used for drug screening research (McBride, BC1965, Doctoral dissertation, University of British Columbia.), and it was mainly used to treat diseases caused by fungal infections in humans (Arkley, V., Attenburrow, J., Gregory, GI, & Walker, T. (1962). J. Chem. Soc. (Resumed). 1260-1268.).
[0003] In recent years, new studies have found that griseofulvin and its derivatives have the activity of inhibiting cancer cell proliferation and anti-plant pathogenic bacteria (Petersen, AB, Andersen, NS, Konotop, G., Hanafiah, NHM, Raab, MS, A.,&Clausen,MH(2017).Eur.J.Med.Chem.130,240-247.;(Bai,YB.,Gao,YQ.,Nie,XD., Tuong, T.-M.-L., Li, D., Gao, J.-M. (2019). J. Agric. Food. Chem. 67(22), 6125-6132.). Summary of the invention
[0004] Based on the inventor's research findings, the present invention provides a series of griseofulvin 4-etherified derivatives, the general structural formula of the derivatives is shown in I:
[0005]
[0006] In Formula I, R 1 Any one of the following substituents:
[0007]
[0008] The preparation method of the 4-etherified derivative of griseofulvin of the present invention comprises: in the presence of an organic solvent and a base, compound II reacts with an alkyl bromide to prepare the 4-etherified derivative of griseofulvin, wherein the structural formula of the compound II is shown in formula II:
[0009]
[0010] A further optional solution is to use a suitable recovery method to recover the reaction product, such as, but not limited to, sequentially concentrating and column chromatography separation to collect the etherified derivative of griseofulvin after the reaction is completed.
[0011] The etherified derivative of griseofulvin at position 4 of the present invention can be used to prepare drugs for preventing and resisting plant pathogens, wherein the plant pathogens include one or more of drugs for apple rot, apple anthracnose, tomato early blight, tomato rot, tobacco brown spot, tomato gray mold and apple dry rot.
[0012] The derivatives of the invention have the advantages of high activity, small toxicity and side effects, etc. DETAILED DESCRIPTION
[0013] Unless otherwise specified, the scientific and technical terms used herein are understood according to the knowledge of ordinary technicians in the relevant fields.
[0014] The structures of the derivative structures provided by the present invention (compounds 01, 02, 03, 04, 05, 06, 07, 08 and 09) are respectively:
[0015]
[0016] The synthetic route of the derivative of the present invention is as follows:
[0017]
[0018] Reaction conditions b represent an alkyl bromide, a base and an organic solvent.
[0019] The corresponding preparation method comprises: in the presence of an organic solvent and a base, compound II reacts with an alkyl bromide to prepare an etherified derivative at position 4 of Griseofulvin. After the reaction is completed, the product is recovered. For example, the etherified derivative at position 4 of Griseofulvin can be obtained by direct concentration and column chromatography separation. In the specific scheme, those skilled in the art can select suitable organic solvents and bases according to the purpose of the present invention, wherein the organic solvent is, for example, but not limited to, acetone and THF; the base is, for example, but not limited to, potassium carbonate, sodium carbonate and cesium carbonate.
[0020] The compound II described in the present invention is a compound in which the methoxy group at the 4-position of Griseofulvin is demethylated to become a hydroxyl group, and its general structural formula is as follows:
[0021]
[0022] The preparation method can be adopted from the literature (Bai Yu-Bin, Gao Yu-Qi, Nie Xiao-Di, Tuong Thi-Mai-Luong, Li Ding, Gao Jin-Ming. Antifungal activity of griseofulvin derivatives against phytopathogenic fungi in vitro and in vivo and three-dimensional quantitative structure-activity relationship analysis. J. Agric. Food. Chem. 2019, 67 (22), 6125-6132.; M H., Harris P., Gotfredsen C H., et al. Synthesis and single crystal X-ray analysis of two griseofulvin metabolites. Tetrahedron Letters. 2010, 51(45): 5881-5882.) The synthesis method of compound II used in the following examples is:
[0023] Magnesium chips (0.518 g, 21.6 mmol) and iodine (1.828 g, 7.2 mmol) were placed in a reaction vessel. Under argon protection, a mixed solvent of anhydrous ether (4 mL) and dry toluene (8 mL) was added to react slowly. After the reaction stabilized, refluxed at 80 ° C for about 30 minutes until the solution became colorless to prepare MgI 2 The solution was added dropwise to a toluene solution (10 mL) containing Griseofulvin (1.411 g, 4 mmol) under argon protection, and heated to 80°C. After reflux for 4 hours until the reaction was complete, it was cooled to room temperature, water (20 mL) and a small amount of sodium thiosulfate were added, and finally 5% hydrochloric acid (10 mL) was added. The mixture was extracted 3 times with EtOAc (20 mL) and washed with anhydrous Na 2 SO 4 Dry and concentrate, eluent (CH 2 Cl 2 :MeOH:AcOH=97:2:1) was separated and purified by column chromatography to obtain the desired product with a yield of more than 80%.
[0024] The structural formula of the raw material Griseofulvin used in the synthesis of the above-mentioned compound II is as follows:
[0025]
[0026] The Griseofulvin (CAS No. 126-07-8) used was purchased from Aladdin Reagent (Shanghai) Co., Ltd. with a purity of 97.0%.
[0027] The following is an example of the synthesis of the derivatives of the present invention given by the inventor. It should be noted that the temperatures and concentrations involved in this article are approximate values for the purpose of illustration. In the specific scheme, the skilled person can select the material ratio, concentration, temperature (the optional range is room temperature to the temperature corresponding to the boiling point of the reaction solvent), organic solvent, reactant addition sequence, material addition method, reaction heating method, and product recovery involved in the method according to the disclosure of the present invention using a conventional experimental period to achieve the purpose of the present invention.
[0028] Example 1: Preparation of 4-propargyl Griseofulvin (Compound 01)
[0029] At room temperature, compound II (0.5 mmol) was dissolved in dry acetone (6 mL), and then propargyl bromide (0.6 mmol) and potassium carbonate (0.75 mmol) were added; the reaction mixture was refluxed under oil bath heating and monitored by TLC. After the reaction was complete, it was cooled to room temperature, an appropriate amount of silica gel was added and the sample was stirred by rotary evaporation, and then the eluent (CH 2 Cl 2 :CH 3 OH=40:1–100:1), and the etherified target product was obtained by separation and purification by column chromatography.
[0030] Yield: 95%; white solid, mp: 176–178°C.
[0031] NMR data: 1 H NMR (400 MHz, CDCl 3 )δ6.37(s,1H,H-5),5.54(s,1H,H-3′),4.96–4.84(m,2H,-OCH 2 -),4.03(s,3H,H-10),3.62(s,3H,H-11),3.02(dd,J=16.5,13.5Hz,1H,H-5′),2.84(dqd,J=13.3,6.8 ,4.9Hz,1H,H-6′),2.63(s,1H,CH≡C-),2.43(dd,J=16.6,4.6Hz,1H,H-5′),0.96(d,J=6.7Hz,3H,H-8).13 C NMR (100 MHz, CDCl 3 )δ197.17(C-4′),192.48(C-3),170.83(C-2′),169.65(C-7a),164.40(C-6),155.42( C-4),105.63(C-3a),105.02(C-3′),98.25(C-7),91.92(C-5),90.92(C-2),77.68(CH≡ C -),77.08( C H≡C-),57.27(-OCH 2 -),57.21(C-10),56.84(C-11),40.13(C-5′),36.57(C-6′),14.38(C-8).HR-MS(ESI):m / z calcd.for C 19 H 17 C1O 6 H:376.0714; found:377.0792[M+H] + .
[0032] The structural formula of the compound prepared in this example is:
[0033]
[0034] Example 2: Preparation of 4-allyl Griseofulvin (Compound 02)
[0035] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is allyl bromide, and a white solid is obtained.
[0036] Yield: 72%; Melting point: 200–202°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ6.14(s,1H,H-5),6.06(ddt,J=17.2,10.4,5.1Hz,1H,CH 2 =C H -),5.56–
[0037] 5.46 (m, 2H, H-3′, -CH=C H 2 ),5.36(dd,J=10.5,1.4Hz,1H,-CH=C H 2 ),4.71(d,J=5.2Hz,2H,-OCH 2-),3.99(s,3H,H-10),3.61(s,3H,H-11),3.03(dd,J=16.7,13.5Hz,1H,H-5′),2.83(dqd,J=13 .5,6.7,4.7Hz,1H,H-6′),2.41(ddd,J=16.7,4.7,0.7Hz,1H,H-5′),0.96(d,J=6.7Hz,3H,H-8). 13 C NMR (100 MHz, CDCl 3 )δ197.20(C-4′),192.34(C-3),170.97(C-2′),169.57(C-7a),164.47(C-6),156.85(C-4),131.74(CH 2 =CH-),118.94(CH 2 =CH-),105.45(C-3a),104.91(C-3′),97.34(C-7),91.02(C-5),90.81(C-2),70.17(-OCH 2 -),57.08(C-10),56.80(C-11),40.11(C-5′),36.58(C-6′),14.35(C-8).HR-MS(ESI):m / zcalcd.for C 19 H 19 C1O 6 Na:401.0768; found:401.0779[M+Na] + .
[0038] The structural formula of the compound prepared in this example is:
[0039]
[0040] Example 3: Preparation of 4-butyl Griseofulvin (Compound 03)
[0041] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is bromobutane, and a white solid is obtained.
[0042] Yield: 86%, melting point: 145–146°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ6.11(s,1H,H-5),5.53(s,1H,H-3′),4.16–4.06(m,2H,-OCH 2-),4.00(s,3H,H-10),3.61(s,3H,H-11),3.05(dd,J=16.7,13.5Hz,1H,H-5′),2.83(dqd,J=13. 6,6.8,4.8Hz,1H,H-6′),2.41(dd,J=16.7,4.7Hz,1H,H-5′),1.87(dq,J=9.2,6.6,5.8Hz,2H,-CH 2 -),1.52(dqd,J=14.7,7.4,2.2Hz,2H,-CH 2 -), 1.05–0.90(m,6H,H-8,-CH 3 ). 13 C NMR (100 MHz, CDCl 3 )δ197.23(C-4′),192.25(C-3),171.08(C-2′),169.58(C-7a),164.55(C-6),157.62(C -4),105.32(C-3a),104.90(C-3′),96.95(C-7),90.75(C-5),90.38(C-2),69.34(-OCH 2 -),57.08(C-10),56.79(C-11),40.13(C-5′),36.63(C-6′),30.90(-CH 2 -),19.21(-CH 2 -), 14.37(C-8), 13.95(-CH 3 ).HR-MS(ESI):m / z calcd.for C 20 H 23 C1O 6 Na:417.1081; found:417.1086[M+Na] + .
[0043] The structural formula of the compound prepared in this embodiment is:
[0044]
[0045] Example 4: Preparation of 4-cyclopropane-substituted methyl Griseofulvin (Compound 04)
[0046] The synthesis method of this example is different from that of Example 1 in that the alkyl bromide used is methyl bromide substituted with cyclopropane, and a white solid is obtained.
[0047] Yield: 60%, melting point: 174–176°C; NMR data: 1H NMR (400 MHz, CDCl 3 )δ6.10(s,1H,H-5),5.53(s,1H,H-3′),4.04–3.89(m,5H,-OCH 2 -,H-10),3.62(s,3H,H-11),3.05(dd,J=16.7,13.5Hz,1H,H-5′),2.84(dqd,J=13 .6,6.7,4.7Hz,1H,H-6′),2.41(dd,J=16.7,4.7Hz,1H,H-5′),1.37–1.32(m,1H,-C H -C 2 H 4 ),0.96(d,J=6.7Hz,3H,H-8),0.76–0.62(m,2H,-CH 2 -),0.40(dt,J=6.2,4.7Hz,2H,-CH 2 -). 13 C NMR (100 MHz, CDCl 3 )δ197.24(C-4′),192.24(C-3),171.08(C-2′),169.61(C-7a),164.50(C-6),157.48(C -4),105.45(C-3a),104.89(C-3′),97.12(C-7),90.88(C-5),90.74(C-2),74.42(-OCH 2 -),57.09(C-10),56.78(C-11),40.12(C-5′),36.65(C-6′),14.37(C-8),9.92(- C HC 2 H 4 ),3.66(-CH 2 -),3.62(-CH 2 -).HR-MS(ESI):m / z calcd.for C 20 H 21 C1O 6 Na:415.0924; found:415.0928[M+Na] + .
[0048] The structural formula of the compound prepared in this embodiment is as follows:
[0049]
[0050] Example 5: Preparation of 4-methoxy-substituted methyl Griseofulvin (Compound 05)
[0051] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is methyl bromide substituted with methoxy group, and a white solid is obtained.
[0052] Yield: 67%, melting point: 124–125°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ6.48(s,1H,H-5),5.55(s,1H,H-3′),5.33(s,2H,-OCH 2 O-),4.00(s,3H,H-10),3.63(s,3H,H-11),3.53(s,3H,-OCH 3 ), 3.02(dd,J=16.5,13.5Hz,1H,H-5′), 2.86(dtd,J=13.4,6.8,4.9Hz,1H,H-6′), 2.43(dd,J=16.6,4.6Hz,1H,H-5′), 0.96(d,J=6.6Hz,3H,H-8). 13 C NMR (100 MHz, CDCl 3 )δ197.21(C-4′),192.65(C-3),170.94(C-2′),169.44(C-7a),164.53(C-6),15 5.53(C-4),105.75(C-3a),104.99(C-3′),98.31(C-7),95.49(C-5),93.27(-OCH 2 O-),90.83(C-2),57.24(C-10),57.11(-OCH 3 ),56.84(C-11),40.11(C-5′),36.61(C-6′),14.40(C-8).HR-MS(ESI):m / z calcd.for C 18 H 19 C1O 7 Na:405.0717; found:405.0728[M+Na] + .
[0053] The structural formula of the compound prepared in this embodiment is:
[0054]
[0055] Example 6: Preparation of 4-O-Fluorobenzyl Griseofulvin (Compound 06)
[0056] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is o-fluorobenzyl bromide to obtain a white solid.
[0057] Yield: 83%, melting point: 212–213℃; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.71–7.64(m,1H,ArH),7.37–7.29(m,1H,ArH),7.19(d,J=1.0Hz,1H,ArH), 7.12–7.04(m,1H,ArH),6.25(s,1H,H-5),5.54(s,1H,H-3′),5.31(s,2H,-OCH 2 -),3.99(s,3H,H-10),3.62(s,3H,H-11),3.04(dd,J=16.6,13.5Hz,1H,H-5′),2.92 –2.79(m,1H,H-6′),2.43(dd,J=16.7,4.7Hz,1H,H-5′),0.96(d,J=6.7Hz,3H,H-8). 13 C NMR (100 MHz, CDCl 3 )δ197.08(C-4′),192.31(C-3),170.92(C-2′),169.64(C-7a),164.57(C-6),161.26( C-4),158.82(C-3a),156.43(C-3′),130.24(d,J=8.2Hz,ArC),129.58(d,J=3.5Hz,Ar C),124.97(d,J=3.7Hz,ArC),122.68(d,J=13.6Hz,ArC),115.32(d,J=21.0Hz,ArC),1 04.97(C-7),105.99–96.49(m,ArC),91.20(C-5),90.89(C-2),64.55(d,J=4.5Hz,-OCH 2 -),57.16(C-10),56.80(C-11),40.16(C-5′),36.62(C-6′),14.38(C-8).HR-MS(ESI):m / z calcd.for C 23 H 20 ClFO 6 Na:469.0830; found:469.0832[M+Na] + .
[0058] The structural formula of the compound prepared in this embodiment is:
[0059]
[0060] Example 7: Preparation of 4-3-Methylenethienyl Griseofulvin (Compound 07)
[0061] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is 3-bromomethylthiophene, and a white solid is obtained.
[0062] Yield: 73%, melting point: 212–214°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.42–7.39(m,1H,-S-CH=),7.35(dd,J=5.0,3.0Hz,1H,-SC H =CH-),7.17(dd,J=5.0,1.3Hz,-S-CH=C H -),6.18(s,1H,H-5),5.54(s,1H,H-3′),5.27(dd,J=2.6,1.0Hz,2H,-OCH 2 -),3.96(s,3H,H-10),3.62(s,3H,H-11),3.04(dd,J=16.7,13.5Hz,1H,H-5′),2.85(dtd,J=13 .4,6.7,4.7Hz,1H,H-6′),2.43(ddd,J=16.7,4.7,0.6Hz,1H,H-5′),0.96(d,J=6.7Hz,3H,H-8). 13 C NMR (100 MHz, CDCl 3 )δ197.15(C-4′),192.32(C-3),170.95(C-2′),169.58(C-7a),164.45(C-6),156.74(C-4),136.41(-S- C H=),126.97
[0063] (-S- C H=CH-), 126.42(-S-CH= C H-), 123.22(-S-CH C -),105.61(C-3a),104.94(C-3′),97.58(C-7),91.42(C-5),90.85(C-2),67.44(-OCH 2-),57.10(C-10),56.81(C-11),40.12(C-5′),36.60(C-6′),14.37(C-8).HR-MS(ESI):m / z calcd.for C 21 H 19 C1O 6 SNa:457.0489; found:457.0488[M+Na] + .
[0064] The structural formula of the compound prepared in this embodiment is:
[0065]
[0066] Example 8: Preparation of 4-3-Methylenethienyl Griseofulvin (Compound 08)
[0067] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is o-fluorobenzyl bromide to obtain a white solid.
[0068] Yield: 55%, melting point: 275–276°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ7.99(d,J=8.4Hz,2H,ArH×2),7.59(d,J=8.5Hz,2H,ArH×2),6.16(s,1H,H-5),5.55(s,1H,H-3′),5.31(s,2H,-OCH 2 -),3.96(s,3H,H-10),3.63(s,3H,H-11),3.04(dd,J=16.7,13.5Hz,1H,H-5′),2.91–2.79(m,1H,H-6′),2.60(s,3H,-CH 3 ), 2.42 (d, J = 4.6Hz, 1H, H-5′), 0.97 (d, J = 6.6Hz, 3H, H-8). 13 C NMR (100 MHz, CDCl 3 )δ197.73(-CO-),197.01(C-4′),192.37(C-3),170.84(C-2′),169.67(C-7a),164.52(C-6),156.38(ArC),140.71(C-4),1 37.08(ArC),128.98(ArC),126.80(ArC),105.67(C-3a),105.01(C-3′),97.99(C-7),91.43(C-5),90.96(C-2),70.44(-OCH2 -),57.14(C-10),56.83(C-11),40.15(C-5′),36.61(C-6′),26.80(-CH 3 ),14.39(C-8).HR-MS(ESI):m / z calcd.for C 25 H 23 C1O 7 Na:493.1030; found:493.1035[M+Na] + .
[0069] The structural formula of the compound prepared in this embodiment is:
[0070]
[0071] Example 9: Preparation of 4-cyclopentyl Griseofulvin (Compound 09)
[0072] The synthesis method of this embodiment is different from that of embodiment 1 in that the bromoalkane used is bromocyclopentane, and a white solid is obtained.
[0073] Yield: 43%, melting point: 202–204°C; NMR data: 1 H NMR (400 MHz, CDCl 3 )δ6.11(s,1H,H-5),5.52(s,1H,H-3′),4.88(ddd,J=7.9,5.3,3.8Hz,1H,-OC H -),3.99(s,3H,H-10),3.61(s,3H,H-11),3.04(dd,J=16.7,13.5Hz,1H,H-5′),2.82(ddd,J= 13.5,6.8,4.8Hz,1H,H-6′),2.40(ddd,J=16.7,4.7,0.7Hz,1H,H-5′),2.04–1.90(m,4H,-CH 2 -×2),1.90–1.77(m,2H,-CH 2 -),1.69–1.58(m,2H,-CH 2 -), 0.95 (d, J = 6.7 Hz, 3H, H-8). 13 C NMR (100 MHz, CDCl 3)δ197.23(C-4′),192.19(C-3),171.16(C-2′),169.65(C-7a),164.32(C-6),156.82(C-4),105.69(C-3a),104.82(C-3′), 96.69(C-7),91.83(C-5),90.67(C-2),81.67(-OCH-),57.01(C-10),56.77(C-11),40.10(C-5′),36.65(C-6′),33.02(-CH 2 -),32.88(-CH 2 -),24.19(-CH 2 -),24.17(-CH 2 -),14.37(C-8).HR-MS(ESI):m / z calcd.for C 21 H 23 C1O 6 Na:429.1081; found:429.1087[M+Na] + .
[0074] The structural formula of the compound in this embodiment is:
[0075]
[0076] Example 10: Determination of the anti-plant pathogenic activity of the compounds in the above examples
[0077] The mycelium growth rate inhibition method was used to test the activity of Griseofulvin derivatives against seven plant pathogenic fungi, the target fungi being apple anthracnose, tomato early blight, tomato rot, tobacco brown spot, tomato gray mold and apple dry rot. The results showed that these compounds had good antibacterial activity.
[0078] The specific implementation method is: at about 50°C, under sterile conditions, prepare PDA culture medium plates (culture dish diameter 90 mm) containing the compounds involved in the present invention at a concentration of 100 μg / mL, inoculate the above-mentioned pathogens after the culture medium solidifies, repeat 3 times each, and culture at a constant temperature of 28°C. After culturing for 48 or 72 hours, take out the culture dish, measure the colony diameter with a caliper (measure twice in a cross-section and take the average value) and make a record; if contamination is found, the test must be repeated.
[0079] Finally, the activity preliminary screening results were calculated, and the commercialized oxazolidinone was used as the positive control. The results were expressed as inhibition rate, and the specific formula is as follows:
[0080] Antibacterial rate (%) = (C-T) / (C-4mm) × 100%
[0081] In the formula, C represents the colony diameter of the blank culture medium, and T represents the colony diameter of the sample or positive control. The results are shown in Table 1.
[0082] Table 1 Plant pathogen activity test results of compounds at 100 μg / mL
[0083]
[0084] Notes: Cs, Cytospora sp., apple rot; Fs, Alternaria solani Sorauer, tomato early blight; Aa, Alternaria alternate, tobacco red star; Bs, Botrytis sp., tomato rot; Bc, Botrytis cinerea Pers., tomato gray mold; Cg, Colletotrichum gloeosporioides, apple anthracnose; Bd, Botryosphaeria dothidea, apple dry rot; Hym., Hymexazol.
[0085] IC analysis was performed on the compounds with an inhibition rate of more than 70% in Table 1. 50 For the precise test of activity, the corresponding compounds were prepared into drug-containing culture medium plates with different concentrations such as 100, 50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.3906, 0.1953, 0.0977, and 0.0488 μg / mL, and commercialized oxazolidinone was used as a positive control. Finally, the IC was calculated based on the inhibition rate of different concentrations. 50 The results are shown in Table 2.
[0086] Table 2 IC of compounds against plant pathogens 50 value
[0087]
[0088] As can be seen from Tables 1 and 2, among the 9 Griseofulvin derivatives of the present invention, compound 01 showed very good inhibitory activity against all seven plant pathogenic fungi tested, with IC 50The values were 1.84±0.01μg / mL, 1.32±0.01μg / mL, 1.28±0.00μg / mL, 2.84±0.22μg / mL, 2.04±0.12μg / mL, 0.06±0.02μg / mL, 1.35±0.07μg / mL, especially the activity against apple anthracnose reached 0.06±0.02μg / mL, which was much better than the positive control Hym. In addition, compounds 02, 06, and 07 also showed very good inhibitory activity against apple anthracnose fungi IC 50 The values were 4.05±0.46μg / mL, 1.92±0.19μg / mL, and 3.82±0.09μg / mL, respectively. In addition, compound 02 also showed good inhibitory activity against tomato rot fungi, IC 50 The value is 3.93±0.80μg / mL. When the compounds involved in the present invention are used as anti-plant pathogenic bacteria drugs, the compounds involved in the present invention or these compounds as active ingredients can be mixed with a carrier or diluent allowed in the water body, or these compounds can be used as the main ingredients to prepare various commonly used dosage forms, such as emulsions, hydrates, flowable agents, water solvents, etc., and used as preventive or / and anti-plant pathogenic bacteria drugs.
Claims
1. A 4-etherified derivative of griseofulvin, the general structural formula of which is shown in I: In formula I, R1 is selected from any one of the following substituents: 。 2. The method for preparing the etherified derivative of griseofulvin at position 4 according to claim 1, characterized in that: The method comprises: in the presence of an organic solvent and a base, compound II reacts with an alkyl bromide to prepare a 4-etherified derivative of griseofulvin, wherein the structural formula of the compound II is as shown in formula II: II.
3. The preparation method according to claim 2, characterized in that: After the reaction is completed, the products are concentrated and separated by column chromatography to collect the 4-etherified derivative of griseofulvin.
4. The preparation method according to claim 2, characterized in that: The organic solvent is selected from a mixture of one or more of acetone and THF.
5. The preparation method according to claim 2, characterized in that: The base is selected from one of potassium carbonate, sodium carbonate and cesium carbonate.
6. Use of the etherified derivative of griseofulvin at position 4 according to claim 1 for preparing drugs for preventing and resisting apple rot, apple anthracnose, tomato early blight, tomato rot, tobacco brown spot, tomato gray mold or apple dry rot.
Citation Information
Patent Citations
Griseofulvin compound
CN108779089A
